Profile data is unavailable for this security.
About the company
Nordic Nanovector ASA is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
- Revenue in NOK (TTM)--
- Net income in NOK--
- LocationNordic Nanovector ASAKjelsasveien 168 BOSLO 0884NorwayNOR
- Phone+47 22183301
- Fax+47 22580007
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|NANOV:OSL since |
|Apim Therapeutics As||Announced||21 Nov 2022||21 Nov 2022Announced||-21.92%||--|
|Apim Therapeutics As||Announced||09 Nov 2022||09 Nov 2022Announced||-36.63%||50.09m|